Evaluation of the PACE/PACENET BHL Caregiver Program
Launched by UNIVERSITY OF PENNSYLVANIA · Jun 2, 2015
Trial Information
Current as of October 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an observational study looking at how well the Caregiver Outreach and Telehealth Education Program (COTP) within the Behavioral Health Laboratory (BHL) works for caregivers of people with dementia who are part of the PACE/PACENET program. Researchers will review existing program data and conduct one follow-up interview to see if the COTP helps both the caregiver and the person with dementia. The main thing they’ll look at is a 6‑month check of dementia-related symptoms and caregiver burden using a special checklist. They’ll also look at caregiver well-being, such as satisfaction with caregiving, how capable they feel, the demands they face, and whether they worry about the person they care for needing placement in a facility. A secondary focus is whether caregiver participation affects the caregiver’s view of the possibility of institutionalizing the care recipient.
Eligible participants are adults (18 and older) who are caregivers of PACE/PACENET beneficiaries enrolled in the BHL COTP and who have a relative with clinically meaningful cognitive impairment or dementia. The care recipient’s impairment is identified through baseline screening tests or a dementia diagnosis, and the caregiver must agree to allow the study to use retrospective program data and to take part in the 6‑month outcome interview. The study is being led by the University of Pennsylvania’s CREST program and is conducted at a site in Philadelphia, with about 350 caregiver–care recipient pairs targeted. Results have not yet been reported, and the study is ongoing with data collection through a 6‑month follow‑up after the initial program term.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 18 and older, males and females.
- • 2. The beneficiary screened positive for clinically significant cognitive impairment (BOMC score \> 14) during the Care Recipient Baseline BHL COTP interview and agreed to allow COPT staff to speak with a CG, OR, the beneficiary could not complete the Care Recipient Baseline BHL COTP interview at all, agreed to allow COPT staff to speak with a CG on their behalf, and the CG verified that the beneficiary has clinically significant cognitive impairment (via AD8 score of 2 or more) and/or a dementia diagnosis made by a health care provider.
- • 3. CG provides verbal informed consent to the use of retrospective clinical BHL COTP data and participation in the 6 Month Outcome Research Evaluation at the completion of the 3 Month Program Termination visit.
- Exclusion Criteria:
- • Not meeting the inclusion criteria listed above.
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Mary Beth Gibbons, PhD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials